TheraRadar
Data updated: May 26, 2026

ZOLPIMIST (zolpidem tartrate)

Sleep Approved 2008-12-19
1
Indication
--
Phase 3 Trials
17
Years on Market

Details

Status
Discontinued
First Approved
2008-12-19
Patent Cliff
2032

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
SPRAY, METERED

Companies

Active Ingredient: ZOLPIDEM TARTRATE

ZOLPIMIST Approval History

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
5 FDA actions from 2008 to 2019
Aug 2019 SUPPL
Label · Labeling
Feb 2019 SUPPL
Label · Labeling
Sep 2011 SUPPL
Update · REMS

What ZOLPIMIST Treats

1 FDA approvals

Originally approved for its first indication in 2008 .

  • Other (1)
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT03774810 R01 results posted 831801 R01AG054521-01A1 Ph 4 completed Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
NCT02783729 SUNRISE 1 results posted E2006-G000-304 2015-004347-39 Ph 3 completed Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
NCT03307005 results posted IRB00142395 Ph 4 completed Improving Sleep Quality in Heart Failure
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZOLPIMIST FDA Label Details

View full patent landscape →
1 OB patents · 1 families · 15 international docs across 7 countries

ZOLPIMIST Patents & Exclusivity

Latest Patent: Aug 2032

Patents (1 active)

US8236285 Expires Aug 7, 2032
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for ZOLPIMIST

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2032
  • 1 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.